SPI Pharma has been solving formulation challenges using superior functional materials.
01 1SPI Pharma Inc
02 4SPI Pharma, Inc.
03 1Aurobindo Pharma Limited
04 2Fagron Inc
05 1J.M. Huber Micropowders, Inc.
06 1Liquid Quimica Mexicana, S.A. de C.V.
07 7Minteq U K LTD
08 4Omya Inc.
09 1Particle Dynamics International, LLC
10 14Specialty Minerals Incorporated
01 30Calcium Carbonate
02 1Calcium Carbonate Mag. Hydroxide
03 1Calcium Carbonate Magnesium Hydroxide
04 2Precipitated Calcium Carbonate
05 1SyrSpend SF Alka
06 1SyrSpend SF Alka Cherry
01 4France
02 1India
03 1Mexico
04 2Netherlands
05 28U.S.A
SPI Pharma has been solving formulation challenges using superior functional materials.
NDC Package Code : 58103-132
Start Marketing Date : 2019-08-12
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (90kg/100kg)
Marketing Category : DRUG FOR FURTHER PROCESSING
SPI Pharma has been solving formulation challenges using superior functional materials.
CALCIUM CARBONATE; MAGNESIUM HYDROXIDE
NDC Package Code : 58103-141
Start Marketing Date : 2023-08-23
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (77.5kg/100kg 16kg/100kg)
Marketing Category : DRUG FOR FURTHER PROCESSING
SPI Pharma has been solving formulation challenges using superior functional materials.
CALCIUM CARBONATE; MAGNESIUM HYDROXIDE
NDC Package Code : 58103-142
Start Marketing Date : 2023-08-23
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (77.5kg/100kg 16kg/100kg)
Marketing Category : DRUG FOR FURTHER PROCESSING
SPI Pharma has been solving formulation challenges using superior functional materials.
NDC Package Code : 58103-134
Start Marketing Date : 2020-01-29
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (58kg/100kg)
Marketing Category : DRUG FOR FURTHER PROCESSING
SPI Pharma has been solving formulation challenges using superior functional materials.
NDC Package Code : 58103-143
Start Marketing Date : 2023-11-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (90kg/100kg)
Marketing Category : DRUG FOR FURTHER PROCESSING
CALCIUM CARBONATE; STARCH, CORN; SUCRALOSE
NDC Package Code : 51552-1139
Start Marketing Date : 2012-01-02
End Marketing Date : 2026-06-18
Dosage Form (Strength) : POWDER (1g/g 1g/g 1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
CALCIUM CARBONATE; STARCH, CORN; SUCRALOSE
NDC Package Code : 51552-1201
Start Marketing Date : 2012-01-02
End Marketing Date : 2028-06-17
Dosage Form (Strength) : POWDER (1g/g 1g/g 1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 53004-0440
Start Marketing Date : 2003-01-24
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 53004-0460
Start Marketing Date : 2003-01-24
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 11737-200
Start Marketing Date : 2005-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (0.95kg/kg)
Marketing Category : DRUG FOR FURTHER PROCESSING
65
PharmaCompass offers a list of Calcium Carbonate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Calcium Carbonate manufacturer or Calcium Carbonate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Calcium Carbonate manufacturer or Calcium Carbonate supplier.
PharmaCompass also assists you with knowing the Calcium Carbonate API Price utilized in the formulation of products. Calcium Carbonate API Price is not always fixed or binding as the Calcium Carbonate Price is obtained through a variety of data sources. The Calcium Carbonate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Di-Gel Tablets manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Di-Gel Tablets, including repackagers and relabelers. The FDA regulates Di-Gel Tablets manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Di-Gel Tablets API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Di-Gel Tablets manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Di-Gel Tablets supplier is an individual or a company that provides Di-Gel Tablets active pharmaceutical ingredient (API) or Di-Gel Tablets finished formulations upon request. The Di-Gel Tablets suppliers may include Di-Gel Tablets API manufacturers, exporters, distributors and traders.
click here to find a list of Di-Gel Tablets suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Di-Gel Tablets as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Di-Gel Tablets API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Di-Gel Tablets as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Di-Gel Tablets and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Di-Gel Tablets NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Di-Gel Tablets suppliers with NDC on PharmaCompass.
We have 8 companies offering Di-Gel Tablets
Get in contact with the supplier of your choice:
